RxDoctor Payments Data

Sandra Hall

Adult Health · Des Moines, IANPI 1760938591

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $370 and has fallen 88.9% since, to $41 in 2025.

$671in general payments, 2019–2025

Across 22 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$151
  • Boston Scientific$136
  • E.r. Squibb & Sons, L.L.C.$118
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$92
  • AbbVie$84
  • Novo Nordisk$40
  • plus $51 from 2 others

What the payments were for

  • Food & beverage$671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 80th percentile of 77 adult health providers in Iowa.

See all adult health providers in Iowa

Medicare billing

Part B allowed, 2024
$54,348
Medicare patients
594
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban554$402,836
EntrestoSacubitril/Valsartan150$119,567
XareltoRivaroxaban100$103,715
JardianceEmpagliflozin20$23,434
FarxigaDapagliflozin Propanediol15$11,551
Metoprolol Succinate970$10,367
Repatha SureclickEvolocumab13$9,388
BrilintaTicagrelor18$9,070
Atorvastatin Calcium639$5,548
Bisoprolol Fumarate197$4,906
Rosuvastatin Calcium471$4,545
Ezetimibe230$3,865
Bumetanide101$3,784
Isosorbide Mononitrate ErIsosorbide Mononitrate208$3,294
Icosapent Ethyl13$3,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$402,836554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 adult health providers in Iowa.

Other adult health in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →